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Abstract
Apurinic/Apyrmidinic Endonuclease 1/Redox Factor-1 (APE1/Ref-1) is a reductant which is important for vascular
homeostasis. SIRTUIN1 (SIRT1) is a lysine deacetylase that also promotes endothelium-dependent vasorelaxation. We asked
if APE1/Ref-1 governs the redox state and activity of SIRT1, and whether SIRT1 mediates the effect of APE1/Ref-1 on
endothelium-dependent vascular function. APE1/Ref-1 maintains sulfhydryl (thiol) groups of cysteine residues in SIRT1 in
the reduced form and promotes endothelial SIRT1 activity. APE1/Ref-1 stimulates SIRT1 activity by targeting highly
conserved vicinal thiols 371 and 374 which form a zinc tetra-thiolate motif in the deacetylase domain of SIRT1. Cysteine
residues in the N-terminal redox domain of APE1/Ref-1 are essential for reducing SIRT1 and stimulating its activity. APE1/Ref-
1 protects endothelial SIRT1 from hydrogen peroxide-induced oxidation of sulfhydryls and from inactivation. APE1/Ref-1
also promotes lysine deacetylation of the SIRT1 target endothelial nitric oxide synthase (eNOS). SIRT1 mutated at cysteines
371 and 374, which renders it non-reducible by APE1/Ref-1, prevents lysine deacetylation of eNOS by APE1/Ref-1. SIRT1 free
thiol (reduced sulfhydryl) content and deacetylase activity are diminished in all examined tissues of APE1/Ref-1+/2 mice,
including the vasculature. Overexpression of SIRT1 in aortas of APE1/Ref-1+/2 mice restores endothelium-dependent
vasorelaxation and bioavailable nitric oxide (NO) to levels similar to those observed in wild-type mice. Thus, APE1/Ref-1, by
maintaining functionally important cysteine sulfhydryls in SIRT1 in the reduced form, promotes endothelial SIRT1 activity.
This reductive activation of endothelial SIRT1 by APE1/Ref-1 mediates the effect of APE1/Ref-1 on eNOS acetylation,
promoting endothelium-derived NO and endothelium-dependent vasorelaxation.
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Introduction
The NAD+-dependent SIRT1 protein deacetylase, the closest
mammalian ortholog to yeast Silent Information Regulator-2
(Sir2), has myriad roles in different organs, and has gained
enormous attention as a mediator of changes in mammalian
metabolism and physiology [1]. SIRT1 is regulated at the
transcriptional and post-translational levels. It is post-translation-
ally modified by sumoylation [2], and phosphorylation [3]. In
addition, cysteine residues in SIRT1 are S-glutathiolated [4],
nitrosylated [5], and alkylated [6]. Specific cysteine residues in the
catalytic domain of SIRT1 form a zinc tetra-thiolate center, and
are highly conserved from yeast to mammals [7]. Mutation of
these conserved cysteines in yeast Sir2 abolishes its function [8], as
does chelation of zinc [7,9]. The importance of these specific thiol
residues to Sir2 activity, as well as the role of thiol modifications in
general on SIRT1 activity, suggests the presence of endogenous
reductants that regulate the redox status of cysteine residues, and
activity, of SIRT1.
Redox factor-1 (Ref-1) is a ubiquitously expressed protein,
mainly nuclear in localization, which has multiple functions [10].
Also known as Apurinic/Apyrmidinic Endonuclease-1 (APE1), it is
the rate limiting enzyme in the mammalian base excision repair
pathway [11]. As a cellular reductant, APE1/Ref-1 targets many
transcription factors, maintaining functionally important cysteine
residues in these transcription factors in the reduced form [12].
Reduction of these transcription factors by APE1/Ref-1 promotes
their binding to DNA or transcriptional co-activators. In the
endothelium, APE1/Ref-1 is an important mediator of endothelial
homeostasis: it stimulates nitric oxide (NO) production, and
promotes endothelium-dependent vasodilation [13].
SIRT1 binds to and deacetylates APE1/Ref-1, stimulating
APE1/Ref-1-mediated DNA repair [14]. Recognizing the impor-
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tance of cysteine modification in regulating SIRT1 activity, and
the role of APE1/Ref-1 as a cellular reductant, we hypothesized
that the functional impact of the relationship between SIRT1 and
APE1/Ref-1 may be mutual - that APE1/Ref-1 also has an
important role in regulating SIRT1 activity. In this work we asked
if APE1/Ref-1, by reducing thiol (sulfhydryl) moieties of cysteine
residues in SIRT1, is important for SIRT1 activity in endothelial
cells, and whether SIRT1 mediates APE1/Ref-1-stimulated
endothelium-dependent vasorelaxation.
Materials and Methods
Cell Culture, Plasmids, siRNA, and Transfections
Human embryonic kidney (HEK 293) cells were purchased
from American Type Culture Collection and cultured in DMEM
supplemented with 10% FBS and antibiotics. The SIRT1
(C371S/C374S) and APE1/Ref-1 (C65A/C93A) mutants were
created in wild-type cDNA templates (generously provided by T.
Kouzarides and T. Finkel, respectively) by site-directed mutagen-
esis using the QuickChange kit (Stratagene). All mutations were
verified by sequencing. Small interfering RNA for human APE1/
Figure 1. APE1/Ref-1 regulates SIRT1 activity in vitro and in vivo. (A) APE1/Ref-1 increases SIRT1 activity in endothelial cells. APE1/Ref1 was
adenovirally over-expressed (AdAPE1/Ref-1) or knocked down with siRNA (siAPE1/Ref-1) in HUVEC. Inert adenovirus AdLacZ or scrambled siRNA (scr)
were used as controls. Deacetylase activity of immunoprecipitated endogenous SIRT1 was measured. * P,0.05,# p.0.05, (n = 3). (B) Redox-deficient
APE1/Ref-1 does not increase SIRT1 activity. HEK293 cells were transfected with APE1/Ref-1 (WT) or the redox-deficient APE1/Ref-1 (C65A/C93A)
mutant. Deacetylase activity of immunoprecipitated endogenous SIRT1 was measured. * P,0.05, (n = 5). (C) Knockdown of APE1/Ref-1 decreases
SIRT1 activity in HEK293 cells. Cells were transfected with APE1/Ref-1 siRNA or scrambled (scr) siRNA. Deacetylase activity of immunoprecipitated
endogenous SIRT1 was measured. * P,0.05, (n = 5). (D) APE1/Ref-1 stimulates deacetylase activity of SIRT1 in vitro. Recombinant SIRT1 was
incubated with recombinant wild-type (WT) or redox-deficient APE1/Ref-1 (C65A/C93A). Deacetylase activity was measured in the incubation mix. *
P,0.05, (n = 5). In all experiments, deacetylase activity of recombinant SIRT1, or SIRT1 immunoprecipitated from cell lysates, was measured using the
Fluor de LysH Substrate and is expressed in arbitrary fluorescence units (AFU).
doi:10.1371/journal.pone.0065415.g001
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Ref-1 (59-CCU CAA UGU GGC ACA UGA AGA AAU U-39),
and the appropriate scrambled (scr) control siRNA were
purchased from InVitrogen. Cells were transfected with plasmids
and siRNA using Lipofectamine2000 (InVitrogen) per recommen-
dations of the manufacturer. All other reagents were purchased
from Sigma.
Immunoblotting and Immunoprecipitations
Antibodies against SIRT1 (Santa Cruz Biotechnology), APE1/
Ref-1 (Santa Cruz Biotechnology), GST (Santa Cruz Biotechnol-
ogy), Myc epitope (Santa Cruz Biotechnology), eNOS (Santa Cruz
Biotechnology) and Acetylated-Lysine (Cell Signaling) were
purchased. Immunoprecipitations of SIRT1and myc –SIRT1
were carried out with overnight incubation of 2 mg of antibodies
and 1 mg of nuclear extract (Nuclear extraction kit, Cayman) from
cell lysate or tissue homogenate, followed by 30 mL of protein A–
sepharose slurry (Amersham) for 4 hours. Immunoprecipitation of
eNOS and acetyl-lysine was similarly carried out using whole cell
lysate. After washing, immunoprecipitates were boiled in SDS-
PAGE loading buffer, subjected to SDS-PAGE, transferred to
nitrocellulose filter, and probed with the specified primary
antibody and the appropriate peroxidase-conjugated secondary
antibody (Santa Cruz Biotech). Chemiluminescent signal was
developed using Super Signal West Pico or Femto substrate
(Pierce), and blots imaged with a Gel Doc 2000 Chemi Doc system
(BioRad).
Immunohistochemistry
De-parafinnized mouse aortic rings sections were permeabilized
and processed using a Vectastain Universal Quick Kit (Vector
Laboratories, PK-8800). Primary antibody to Acetylated-p53 (Cell
Signaling) was used at a 1:50 dilution followed by biotinylated
secondary antibody, streptavidin peroxidase solution, DAB per-
oxidase substrate, and hematoxylin counterstain. Sections were
digitally imaged with a Zeiss Axiovert 200 microscope.
Quantitative Real time PCR
Total RNA from tissues was isolated by the acid guanidinium
thiocyanate/phenol/chloroform method. Real time PCR was
performed using the Prism 7000 Sequence Detection System
(Applied Biosystems) with the SuperScript III Platinum SYBR
Green One-Step qRT-PCR Kit (InVitrogen). The primer
sequences for mouse SIRT1 are: forward 59- AAT GCT GGC
CTA ATA GAC TTG CA -39, reverse 59- CCG TGG AAT ATG
TAA CGA TTT GG -39. The primer sequences for mouse APE/
Ref-1 are: forward 59- -39, reverse 59- -39. Mouse GAPDH was
used as an internal control. The primer sequences for mouse
GAPDH are: forward, 59-GGC AAA TTC AAC GGC ACA GT-
39; reverse, 59-CGC TCC TGG AAG ATG GTG AT-39.
Free Thiol Content of SIRT1 in Cells and Tissues
Reduced (free) sulfhydryl (thiol) residues in SIRT1 were
detected by a modified biotin-switch assay [15] using biotin-
HPDP as the reactant which covalently binds to reduced
sulfhydryl groups. Nuclear extracts from cells and tissues were
prepared in non-reducing HENT buffers (250 mM Hepes, pH 7.5
1 mM EDTA, 0.1 mM neocuproine, 1% Triton X-100). Typi-
cally, 1 mg of cell lysate and 2 mg of tissue homogenate was used.
Free (reduced) thiols were linked with biotin using Biotin-HPDP
(Santa Cruz Biotechnology). The biotinylated proteins were pulled
down with Streptavidin-agarose. The pulled down proteins were
immunoblotted with SIRT1 or myc antibody.
Free Sulfhydryl Groups (Free Thiol Content) in
Recombinant Proteins
cDNAs of wild-type and mutant SIRT1 and APE1/Ref -1 were
cloned into pGEX expression vector. Proteins were expressed and
induced with isopropyl b-d-thiogalactoside (IPTG) (0.1 mM) in
BL21 (Stratagene) bacterial host strain. Expressed proteins were
purified using glutathione Sepharose beads (Amersham Bioscienc-
es) following batch purification protocol recommended by the
manufacturer. Eluted proteins were dialyzed to remove glutathi-
one. Purity of the eluted fractions was determined by SDS/PAGE
and Coomassie staining. A modified biotin switch approach [15]
was used to measure the reduction of oxidized thiols in
recombinant SIRT1 by recombinant APE1/Ref-1. Reduced
sulfhydryls were first blocked with N-Ethylmaleimide (NEM)
(Sigma). After removing free NEM with dialysis, recombinant
proteins were incubated with biotin-HPDP, immobilized on
Streptavidin-agarose beads and immunoblotted with SIRT1
antibody. Total SIRT1 and APE1/Ref-1 was detected using
GST antibody.
SIRT Activity Assay
The Biomol SIRT1 activity assay (AK-555, Biomol Interna-
tional) was used per manufacturer’s instructions to measure SIRT1
activity. Recombinant SIRT1 (SE239, Enzo) (with and without
pre-incubation with wild-type APE1/Ref-1 or APE1/Ref-1
(C65A/C93A), or SIRT1 immunoprecipitated under non-reduc-
ing conditions from nuclear extracts of cells or tissues, was used.
Fluorescence (Ex. 360 nm, Em. 460 nm) was measured with
CytoFluorTM II, PerSeptive Biosystems. Activity was measured in
the presence and absence of the SIRT1 inhibitor nicotinamide
(NAM 5 mM), and difference in fluorescence units was calculated.
Fluorescence units from immunoprecipitates using non-immune
IgG was subtracted as background.
Mouse Aortic Vascular Reactivity
8–12 week old APE1/Ref-1+/+ and APE1/Ref-1+/2 male mice
were anesthetized and euthanized by rapid cardiac excision. The
descending thoracic aorta was carefully excised and placed in ice-
cold Krebs buffer (118.3 mM NaCl/4.7 mM KCl/2.5 mM
CaCl2/1.2 mM KH2PO4/25 mM NaHCO3/1.2 mM MgSO4/
11 mM glucose/0.0026 mM CaNa2EDTA). The aorta was
cleaned of excess fat, cut transversely into 5–10 rings (2.0–
3.0 mm), each of which was infected with 661011 viral particles
per ml of the AdLacZ and AdSIRT1 adenoviral stocks, and
incubated at 37uC for 24 h. The next day the vessels were placed
in oxygenated chambers (95% O2/5% CO2) superfused with
Krebs buffer solution and maintained at 37uC and pH 7.4. Each
ring was suspended between two wire stirrups in a 5-ml organ
chamber of a four-chamber myograph system (DMT). One stirrup
was connected to a three-dimensional micromanipulator and the
other to a force transducer. The contractile force was recorded
electronically. All rings were stretched to 2,000 mg in 500-mg
increments over a 1-h period to optimize the contractile response
to KCl. One dose of KCl (60 mM) was administered to verify
vascular smooth muscle viability. Cumulative dose–response curve
for phenylephrine (1029 to 1025 M) was obtained by administer-
ing the drug in one-half log doses. Endothelium-dependent
vasodilatation was determined by generating dose–response curves
to acetylcholine. Vasorelaxation evoked by acetylcholine was
expressed as percent contraction determined by the percentage of
inhibition to the preconstricted tension. Endothelium-dependent
NOS-independent vasorelaxation was assessed by generating
dose–response curves to acetylcholine in rings pretreated with
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Figure 2. APE1/Ref-1 increases free thiol content of SIRT1. (A) APE1/Ref-1 reduces thiol residues of SIRT1 in endothelial cells. APE1/Ref1 was
adenovirally over-expressed (AdAPE1/Ref-1) or knocked down with siRNA (siAPE1/Ref-1) in HUVEC. Inert adenovirus AdLacZ or scrambled siRNA (scr)
were used as controls. * P,0.05, (n = 3). (B) Redox-deficient APE1/Ref-1 does not reduce thiol residues of SIRT1 or stimulate SIRT1 activity. HEK293
cells were transfected with APE1/Ref-1 (WT) or the redox-deficient APE1/Ref-1 (C65A/C93A) mutant. * P,0.05, # p.0.05, (n = 3). (C) Knockdown of
APE1/Ref-1 decreases free thiol content of SIRT1 in HEK293 cells. Cells over-expressing SIRT1 were transfected with APE1/Ref-1 siRNA or scrambled
(scr) siRNA. * P,0.05, (n = 3). (D) Cysteines 371 and 374 in the catalytic core domain of SIRT1 are targeted for reduction by APE1/Ref-1. Recombinant
wild-type SIRT1 (WT) and SIRT1 mutated at cysteines 371 and 374 (C371S/C374S) were incubated with wild-type APE1/Ref-1 (WT) or redox-deficient
APE1/Ref-1 (C65A/C93A) in vitro. Reduced cysteines in SIRT1 and total SIRT1 protein were densitometrically quantified. * P,0.05, (n = 3) (E) APE1/Ref-
1 does not reduce thiol residues in SIRT1 mutated at cysteines 371 and 374 in HEK 293 cells. Wild-type (WT) SIRT1 and SIRT1 (C371S/374S), with and
without APE1/Ref-1, were expressed in cells. In all experiments, free thiol content of SIRT1 was determined using a modified biotin-switch assay, and
is expressed after normalization with total SIRT1.
doi:10.1371/journal.pone.0065415.g002
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Figure 3. APE1/ref-1 protects endothelial SIRT1 from oxidative stress-induced inactivation and promotes de-acetylation of
endothelial nitric oxide synthase. (A) H2O2-induced decrease in SIRT1 activity is rescued by APE1/Ref-1. APE1/Ref1 was adenovirally over-
expressed (AdAPE1/Ref-1) or knocked down with siRNA (siAPE1/Ref-1) in HUVEC. Inert adenovirus AdLacZ or scrambled siRNA (scr) were used as
controls. Cells were treated with H2O2 for 30 min. * P,0.05, # p.0.05, (n = 3). (B) H2O2-induced decrease in free thiol content of SIRT1 is rescued by
APE1/Ref-1. APE1/Ref1 was adenovirally over-expressed (AdAPE1/Ref-1) or knocked down with siRNA (siAPE1/Ref-1) in HUVEC. Inert adenovirus
APE1/Ref-1 Reductively Activates SIRT1
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the NOS inhibitor L-NAME (1024 M). NO bioavailability was
measured physiologically by determining the increase in contrac-
tile response to inhibitor L-NAME in rings preconstricted with
phenylephrine (1026 M). Endothelium-independent vasodilatation
was measured by the vasorelaxation evoked by cumulative sodium
nitroprusside in rings preconstricted with phenylephrine (1026 M).
Ethics Statement
All animal experimentation was carried out under humane
standards and was approved by the University of Pittsburgh
Institutional Animal Care and Use Committee.
Statistical Analysis
All experiments were performed at least three times. Data are
expressed as mean 6 SD. Statistical analysis was performed with
SigmaStat. Data in which two conditions were compared were
tested using the Student t-test. Data in which more than two
conditions were compared in a single experiment were tested using
ANOVA or repeated measures of ANOVA as appropriate.
Correlation between variables was evaluated using the Pearson
product method. A P-value of ,0.05 was considered statistically
significant.
Results and Discussion
We first examined if APE1/Ref-1 affects SIRT1 activity in
endothelial cells. APE1/Ref-1 was adenovirally overexpressed or
knocked down with siRNA in HUVEC and the enzymatic activity
of immunoprecipitated SIRT1 measured. Overexpression of
APE1/Ref-1 stimulated endogenous SIRT1 activity, whereas
knockdown of APE1/Ref-1 decreased this activity (Fig. 1A). In
non-endothelial HEK 293 cells as well, overexpression of APE1/
Ref-1 increased, while knockdown of APE1/Ref-1 decreased,
endogenous SIRT1 activity (Fig. 1B, C).
We then asked if APE1/Ref-1 has a direct stimulatory effect on
SIRT1. To do this, the activity of purified recombinant SIRT1
was measured in the presence of recombinant wild-type APE1/
Ref-1. The activity of recombinant SIRT1 in vitro was increased
in the presence of APE1/Ref-1 (Fig. 1D). Thus, in both cells and
in vitro, APE1/Ref-1 stimulates SIRT1 activity, and lack of
APE1/Ref-1 diminishes this activity.
APE1/Ref-1 is a multi-functional protein. One of its principal
functions is reduction of nuclear transcription factors, maintaining
them in the DNA-binding form. Cysteine residues at positions 65
and 93 in APE1/Ref-1 are essential for executing this function
[16]. Hypothesizing that this reducing function of APE1/Ref-1 is
responsible for APE1/Ref-1-stimulated SIRT1 activity, we exam-
ined the effect APE1/Ref-1 mutated at cysteines 65 and 93, which
is devoid of this reducing function, on SIRT1activity. In contrast
to wild-type APE1/Ref-1, the redox-deficient mutant of APE1/
Ref-1 (C65A/C93A) did not stimulate SIRT1 activity in HEK 293
cells (Fig. 1B) or in vitro (Fig. 1D). Thus APE1/Ref-1 stimulates
SIRT1 activity by virtue of its reducing function.
We next examined if APE1/Ref-1 changes the quantity of
reduced cysteine sulfhydryls (free thiol content) of endothelial
SIRT1. APE1/Ref-1 was adenovirally overexpressed or knocked
down with siRNA in HUVEC and free thiol content of
immunoprecipitated SIRT1 assessed. Overexpression of APE1/
Ref-1 increased free thiols in endogenous SIRT1, whereas
knockdown of APE1/Ref-1 decreased free thiol content of
endothelial SIRT1 (Fig. 2A). In non-endothelial HEK 293 cells
as well, overexpression of APE1/Ref-1 increased, while knock-
down of APE1/Ref-1 decreased, free thiols in SIRT1 (Fig. 2B, C).
We then determined if APE1/Ref-1 increases free thiols of
SIRT1 through direct reduction of these residues. To do this, we
examined the effect of purified APE1/Ref-1 on free thiol content
of recombinant SIRT1 in vitro. APE1/Ref-1 dose-dependently
increased the free thiol content of recombinant SIRT1 (Fig. 2D).
In contrast, purified redox-deficient APE1/Ref-1 (C65A/C93A)
did not increase free thiol content of SIRT1 (Fig. 2D). Thus,
APE1/Ref-1, via its redox function, directly reduces cysteine
sulfhydryls in SIRT1.
The deacetylase domain of SIRT1/Sir2 has a zinc tetra-thiolate
center which is highly conserved from yeast to mammals. We
asked if the cysteine residues in SIRT1 which are reduced by
APE1/Ref-1 are in this tetra-thiolate motif. To answer this we
created a mutant of SIRT1 in which two cysteines in this tetra-
thiolate motif are mutated to non-reducible serines (C371S/374S).
The effect of APE1/Ref-1 on free thiol content of SIRT1 (C371S/
374S) in vitro and in cells was then examined. In contrast to wild-
type recombinant SIRT1, the free thiol content of recombinant
SIRT1 (C371S/374S) was not increased by purified APE1/Ref-1
(Fig. 2D). Similarly, in HEK 293 cells, APE1/Ref-1 did not
increase free thiol content of SIRT1 (C371S/374S) (Fig. 2E).
Thus, APE1/Ref-1 targets cysteines 371 and 374, which form the
Zn tetra-thiolate motif in the deacetylase domain of SIRT1, for
reduction.
SIRT1 is prone to redox modifications such as glutathiolation
[4]. Therefore, we asked if the reactive oxygen moiety hydrogen
peroxide can post-translationally modify SIRT1 and affect its
activity in endothelial cells. The activity and free thiol content of
endothelialSIRT1was significantly diminished by hydrogen per-
oxide (Fig. 3A, B). Hydrogen peroxide also inhibited the activity of
recombinant SIRT1 in vitro (Fig. 3C). Thus, hydrogen peroxide
oxidizes cysteine sulfhydryls in endothelial SIRT1, thereby
inhibiting its activity.
APE1/Ref-1 protects endothelial cells from the deleterious
consequences of oxidative stress [17]. Therefore, we asked if
APE1/Ref-1 also protects endothelial SIRT1 for hydrogen
peroxide-induced inactivation. Overexpression of APE1/Ref-1 in
endothelial cells mitigated hydrogen peroxide-induced decrease in
free thiol content and deacetylase activity of SIRT1 (Fig. 3A, B).
Conversely, knockdown of APE1/Ref-1 in endothelial cells led to
AdLacZ or scrambled siRNA (scr) were used as controls. Cells were treated with H2O2 for 3 hrs. * P,0.05, # p.0.05, (n = 3). (C) H2O2 dose-
dependently inactivates SIRT1 in vitro. Recombinant active SIRT1 was treated with H2O2 for 1 hour. * P,0.05, (n = 3) In A-C, deacetylase activity of
recombinant SIRT1, or SIRT1 immunoprecipitated from cell lysates, was measured using the Fluor de LysH Substrate and is expressed in arbitrary
fluorescence units (AFU). Free thiol content of SIRT1 was determined using a modified biotin-switch assay, and is expressed after normalization with
total SIRT1. (D) APE1/Ref-1 rescues SIRT1 from H2O2–induced inactivation in vitro. Recombinant active SIRT1 was treated with H2O2 for 1 hour. *
P,0.05, # p.0.05, (n = 3). (E) APE1/Ref-1 stimulates lysine de-acetylation of endothelial nitric oxide synthase (eNOS). APE1/Ref1 was adenovirally
over-expressed (AdAPE1/Ref-1) or knocked down with siRNA (siAPE1/Ref-1) in HUVEC. Inert adenovirus AdLacZ or scrambled siRNA (scr) were used as
controls. Acetylated lysine was assessed and quantified in immunoprecipitated eNOS. Values are expressed as fold change in acetylated eNOS after
normalization with total eNOS. * P,0.05, # p.0.05, (n = 3). (F) Non-reducible SIRT1 inhibits APE1/Ref-1-stimulated deacetylation of eNOS. APE1/Ref-
1, with or without non-reducible SIRT1 (C371S/C374S) was expressed in HUVEC. Acetylated eNOS was assessed in acetyl-lysine immunoprecipitates. *
P,0.05 compared to control, and ** P,0.01 compared to APE1/Ref-1+ SIRT1 (C371S/C374S), (n = 3).
doi:10.1371/journal.pone.0065415.g003
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a decrease in free thiol content and activity of SIRT1 (Fig. 3A, B).
Purified APE1/Ref-1 also rescued inactivation of recombinant
SIRT1 by hydrogen peroxide in vitro (Fig. 3D). Thus, endogenous
APE1/Ref-1 is obligatory for optimal endothelial SIRT1 activity,
and overexpression of APE1/Ref-1 protects endothelial SIRT1
from inactivation by oxidative stress.
APE1/Ref-1 stimulates the activity of eNOS and increases
endothelial NO [13]. Endothelial nitric oxide synthase (eNOS) is
lysine acetylated and SIRT1 increases eNOS activity by
deacetylating it [18]. We therefore wondered if the effect of
APE1/Ref-1 on endothelial SIRT1 translates into a change in
eNOS acetylation. In endothelial cells, overexpression of APE1/
Ref-1 suppressed lysine acetylation of eNOS, whereas knockdown
of APE1/Ref-1 increased eNOS acetylation (Fig. 3E). This
suggests that activation of endothelial SIRT1 by APE1/Ref-1
translates into deacetylation of eNOS.
Next, we asked if reduction of SIRT1 is required for
deacetylation of eNOS by APE1/Ref-1. We first measured
deacetylase activity of non-reducible SIRT1 (C371S/C374S).
Compared to WT SIRT1, deacetylase activity of SIRT1 (C371S/
C374S) was significantly diminished in both HUVEC and HEK
293 cells (Fig. S1A, and S1B). Moreover, expression of SIRT1
Figure 4. SIRT1 activity and free thiol content is diminished in APE1/Ref-1 heterozygous mice. (A) APE1/Ref-1+/2 mice have decreased
tissue SIRT1 activity. SIRT1 activity was measured in liver, kidney and aorta of APE1/Ref-1+/2mice and APE1/Ref-1+/+ mice. * P,0.05, (n = 3). (B and C)
SIRT1 expression is unchanged in APE1/Ref-1+/2 mice. SIRT1 mRNA (B) and protein (C), and APE1/Ref-1 protein (C) was assessed and quantified in
liver, kidney, heart and aorta of APE1/Ref-1+/+ mice and APE1/Ref-1+/2 mice. mRNA was normalized to GAPDH, and protein to b-actin, and both
expressed as fold relative to APE1/Ref-1+/+ mice. * P,0.05, # p.0.05, (n = 3). (D) Free thiol content of tissue SIRT1 is diminished in APE1/Ref-1+/2
mice. Free thiol content was assessed and densitometrically quantified in kidneys of APE1/Ref-1+/+ and APE1/Ref-1+/2 mice. * P,0.05, (n = 3). (E)
APE1/Ref-1+/2 mice have increased lysine acetylation of endothelial p53. Immunohistochemistry for lysine acetylated p53 was performed in sections
of aortas from APE1/Ref-1+/+ and APE1/Ref-1+/2 mice. Magnification is 406. Percentage of endothelial cells positive for detectable lysine acetylated
p53 was quantified in 20 cells from three separate fields. * P,0.05, (n = 3). Arrows: positive cells identified in the endothelium and media. Deacetylase
activity of SIRT1 immunoprecipitated from nuclear extracts of homogenized tissues was measured using the Fluor de LysH Substrate and is expressed
in arbitrary fluorescence units (AFU). Free thiol content of SIRT1 in nuclear extracts was determined using a modified biotin-switch assay, and is
expressed after normalization with total SIRT1.
doi:10.1371/journal.pone.0065415.g004
Figure 5. SIRT1 rescues impaired endothelium-dependent vasorelaxation in APE1/Ref-1 heterozygous mice. (A) Adenoviral gene
transfer of SIRT1 increases vascular SIRT1 activity. Wild-type SIRT1 was overexpressed ex vivo in aortic sections of APE1/Ref-1+/2 mice using AdSIRT1.
AdLacZ was used as control. SIRT1 protein and activity in whole aortas was determined. * P,0.05, (n = 3) (B) Overexpression of SIRT1 restores
endothelium-dependent vasorelaxation in APE1/Ref-1+/2 mice. Wild-type SIRT1 was overexpressed ex vivo in aortic sections of APE1/Ref-1+/2 mice
using AdSIRT1. AdLacZ was used as control. Acetylcholine-induced endothelium-dependent vasorelaxation was measured in aortic sections of APE1/
Ref-1+/+ mice (¤), APE1/Ref-1+/2 mice infected with AdSIRT1 (&), and APE1/Ref-1+/2 mice infected with AdLacZ (m).* P,0.01 compared with APE1/
Ref-1+/+ and APE1/Ref-1+/2+AdSIRT1 (n = 6). (C) Bioavailable NO in aortic sections of APE1/Ref-1+/+ mice (¤), APE1/Ref-1+/2 mice infected with
AdSIRT1 (&), and APE1/Ref-1+/2 mice infected with AdLacZ (m).*P,0.01 compared with APE1/Ref-1+/+ mice and APE1/Ref-1+/2 mice+AdSIRT1 (n = 5).
(D) Sodium nitroprusside (SNP)-induced endothelium-independent vasorelaxation in aortic sections of APE1/Ref-1+/+ mice (¤), APE1/Ref-1+/2 mice
infected with AdSIRT1 (&), and APE1/Ref-1+/2 mice infected with AdLacZ (m) (n = 4).
doi:10.1371/journal.pone.0065415.g005
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(C371S/C374S) inhibited the activity of endogenous SIRT1 (Fig.
S1C) indicating that it acts in a dominant inhibitory manner.
Capitalizing on this property of SIRT1 (C371S/C374S), we
determined if it can negate APE1/Ref-1-induced deacetylation of
eNOS. In HUVEC, expression of SIRT1 (C371S/C374S)
prevented deacetylation of eNOS by APE1/Ref-1 (Fig. 3F)
indicating that reduction of these cysteine sulfhydryls in SIRT1by
APE1/Ref-1 is obligatory for APE1/Ref-1-induced deacetylation
of eNOS.
We then explored the in vivo significance of the afore-
mentioned relationship between APE1/Ref-1 and SIRT1 using
mice heterozygous for APE1/Ref-1. Compared with wild-type
littermates, aortic tissue of APE1/Ref-1+/2 mice had lower SIRT1
activity (Fig. 4A). Decreased SIRT1 activity was not restricted to
the vasculature, as all tissues examined in APE1/Ref-1+/2 mice
had lower SIRT1 activity than wild-type controls (Fig. 4A).
Diminished tissue SIRT1 activity was not due to down-regulation
of SIRT1, as expression of SIRT1, both at the mRNA and protein
levels, was similar in wild-type and APE1/Ref-1+/2 mice (Fig. 4B,
C). In addition to lower SIRT1 activity in whole aortas,
endothelial SIRT1 activity was also diminished in APE1/Ref-1+/
2 mice, as reflected by an increase in lysine acetylated p53, a
protein that SIRT1 targets for deacetylation (Fig. 4D). Decreased
SIRT1 activity mirrored diminished free thiol content of SIRT1 in
tissues of APE1/Ref-1+/2 mice (Fig. 4E). Therefore, lack of one
allele of APE1/Ref-1 in mice leads to diminished deacetylase
activity and decreased free thiol content of tissue SIRT1.
APE1/Ref-1+/2 mice have impaired endothelium-dependent
vasorelaxation, lower vascular nitric oxide, and are hypertensive
[13]. Similar to the role of APE1/Ref-1 in the endothelium,
SIRT1 promotes vascular nitric oxide availability and endotheli-
um-dependent vasorelaxation [18], inhibits endothelial activation
[19], decreases high-fat diet-induced atherosclerosis [20], and
mediates shear stress-stimulated vascular NO production [21].
Hypothesizing that impaired endothelial vasodilatory function in
APE1/Ref-1+/2 mice may, in part, be due to diminished vascular
SIRT1 activity, we asked if SIRT1 rescues endothelium-depen-
dent vascular dysfunction in these mice. SIRT1 was adenovirally
overexpressed (AdSIRT1) in aortas of APE1/Ref-1+/2 mice. The
adenovirus AdLacZ, expressing the inert E. Coli b-galactosidase
gene, was used as a control. AdSIRT1 increased SIRT1 activity in
aortas of APE1/Ref-1+/2 mice (Fig. 5A). Increase in SIRT1
activity restored acetylcholine-induced endothelium-dependent
vasorelaxation in APE1/Ref-1+/2 mice to that of wild-type
animals (Fig. 5B). In addition, adenoviral overexpression of SIRT1
restored bioavailable NO in aortas of APE1/Ref-1+/2 mice to
levels comparable to those of wild-type mice (Fig. 5C). Endothe-
lium-independent vasorelaxation elicited by the NO donor sodium
nitroprusside (SNP) was similar in the wild-type and APE1/Ref-
1+/2mice and was not affected by SIRT1 overexpression (Fig. 5D).
Thus, SIRT1 overexpression rescues impaired endothelium-
dependent vasorelaxation due to deficiency of APE1/Ref-1.
Identification of SIRT1 as a target of APE1/Ref-1 adds to a
substantial number of proteins reduced by APE1/Ref-1. Many of
these proteins are transcription factors, and their reduction by
APE1/Ref-1 facilitates their binding to DNA or transcriptional co-
activators. Interestingly, some of these same transcription factors
have been identified as targets for deacetylation by SIRT1 [22,23].
This raises the possibility that APE1/Ref-1 and SIRT1 may act in
concert to modulate transcription by these factors. For example,
APE1/Ref-1 reduces cysteines in the DNA-binding domain of c-
jun, promoting binding of the fos-jun complex to DNA, and
Figure 6. Schematic showing oxidation of vicinal thiols in the zinc tetra-thiolate center of the catalytic domain of SIRT1, and their
reduction by APE1/Ref-1.
doi:10.1371/journal.pone.0065415.g006
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stimulating transcriptional activity of activator protein-1 (AP-1)
[24,25]. SIRT1, on the other hand, deacetylates c-fos and c-jun,
inhibiting AP-1 transcriptional activity [23]. Thus, reductive
activation of SIRT1 by APE1/ref-1 may be part of a feedback
loop modulating the activation of the AP-1 transcription complex.
A similar scenario can be envisioned for other transcription factors
such as the tumor suppressor protein p53, and hypoxia-inducible
factor-1a, both of which are targeted by SIRT1 and APE1/Ref-1
[22,26,27,28].
The four cysteine residues in the zinc tetra-thiolate center of
SIRT1 are part of two CXXC (where X is any amino acid) motifs.
All four vicinal thiols in these two motifs are highly conserved,
from yeast Sir2 to mammalian SIRT1 [7]. Two of these thiols are
S-nitrosylated by nitric oxide [5]. Our work examined the effect of
APE1/Ref-1 on the redox status of the other two cysteine residues
in this tetra-thiolate center. Although we did not test whether the
two cysteines subject to modification by NO are also subject to
reduction by APE1/Ref-1, it would not be surprising if that were
the case, given that mutational disruption of any one of the two
CXXC motifs in yeast Sir2 renders the enzyme inactive [8].
Importantly, the vicinal nature of cysteines 371 and 374 lends
these residues to intra-molecular disulfide bond formation by
endogenous oxidants and oxidative stress (Fig. 6), whereas other
cysteines in SIRT1, such as cysteines 67, 268, and 623 which are
also susceptible to post-translational modifications [4,6], not being
vicinal thiols, may not be able to form disulfide bonds in oxidizing
conditions. This could explain why cysteines 371 and 374 were the
residues targeted by APE1/Ref-1 (Fig. 2D, E). However, the
inference that APE1/Ref-1 targets only vicinal thiols in SIRT1
must be tempered by the realization that it can also reduce non-
vicinal cysteine residues in many of its target proteins.
Endothelial SIRT1 has a vital part in choreographing pre- and
post-natal angiogenesis [29]. The redox function of APE1/Ref-1
too, has an important role in neo-vascularization, as evidenced
using selective inhibitors of APE1/Ref-1 in models of retinal
angiogenesis [30]. Given our observations about the importance of
APE1/Ref-1 to endothelial SIRT1 activity, it is tempting to
speculate that redox regulation of SIRT1 by APE1/Ref-1, and
possibly by other cellular reducing equivalents, not only mediates
vasodilation, but may also be relevant to other vital endothelial
functions such as angiogenesis.
Supporting Information
Figure S1 SIRT1 (C371S/C374S) has diminished deace-
tylase activity and acts in a dominant negative fashion.
(A, B) SIRT1 (C371S/C374S) has diminished deacetylase
activity. Deacetylase activity of immunoprecipitated SIRT1
(WT) and SIRT1 (C371S/C374S) expressed in (A) HUVEC and
(B) HEK 293 cells was determined. Values are expressed relative
to SIRT1 (WT). *, ***P,0.05, 0.001 (n= 3–4). (C) SIRT1
(C371S/C374S) inhibits the activity of endogenous SIRT1.
Deacetylase activity of immunoprecipitated total SIRT1 was
measured in HEK 293 cells not expressing ectopic SIRT1 and
those expressing SIRT1 (C371S/C374S). *** P,0.001 (n= 3).
Deacetylase activity of SIRT1 immunoprecipitated from cell
lysates was measured using the Fluor de LysH Substrate.
(TIF)
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